The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

EARLY_PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-30

Study Completion Date

2025-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to assess if glutathione, along with NAC (N-acetyl cysteine) and Alpha lipoic acid (ALA), can help reverse some of the COVID long-haul symptoms.Subjects will be randomized in to one of two groups. Depending on the group they are randomized in to, subjects will be taking either a combination of NAC, Alamax CR, and liposomal GSH or the same three nutritional supplements with a multivitamin and magnesium. Regardless of the group, subjects will be asked questions to assess their COVID symptoms, physical and mental health status. They will also be asked to take blood samples.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Glutathione, Oxidative Stress and Mitochondrial Function in COVID-19

NCT04703036

Covid19

TERMINATED EARLY_PHASE1

Glutathione (GSH) Supplementation After Hospitalization

NCT03166371

Malnutrition

WITHDRAWN NA

Effects of Glutathione (an Antioxidant) and N-Acetylcysteine on Inflammation

NCT01550432

Obesity Hyperlipidemia Insulin Resistance +1 more

COMPLETED NA

Oral Glutathione Supplementation on the Levels of Blood Glutathione

NCT01044277

Healthy Adults

COMPLETED NA

Oral Liposomal Glutathione Supplementation in Healthy Subjects

NCT02278822

Healthy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

No Multivitamin and Magnesium

Subjects randomized into Group A will take the following amount for 28 days

* 4 capsules of NAC (600mg each) once in the morning and once in the evening
* 1 tablet (600mg) of Alamax CR once in the morning and once in the evening
* 8 capsules (250 mg each) of liposomal GSH in the morning and in the evening

Group Type EXPERIMENTAL

NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH)

Intervention Type DRUG

Nutritional supplements hypothesized to help reverse some of the COVID long-haul symptoms.

Multivitamin and Magnesium

Subjects randomized into Group B will be taking a multivitamin and magnesium for 14 days. Afterwards, they will take the following for 14 days.

* 4 capsules of NAC (600mg each) once in the morning and once in the evening
* 1 tablet (600mg) of Alamax CR once in the morning and once in the evening
* 8 capsules (250 mg each) of liposomal GSH in the morning and in the evening

Group Type ACTIVE_COMPARATOR

NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH)

Intervention Type DRUG

Nutritional supplements hypothesized to help reverse some of the COVID long-haul symptoms.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH)

Nutritional supplements hypothesized to help reverse some of the COVID long-haul symptoms.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• Patients with positive COVID testing (AB, RT PCR) and mild-severe symptoms based on COVID symptom list

Exclusion Criteria

• History of a severe sulfa sensitivity (i.e., anaphylaxis, Stevens Johnson Syndrome), allergy to meat products and/or gelatin (alpha gal allergy) and/or a history of an allergic or adverse reaction to NAC, alpha lipoic acid and/or GSH.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No